Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models.
Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, Ilan N, Vlodavsky I, Abramovitch R. Zcharia E, et al. Among authors: casu b. FASEB J. 2005 Feb;19(2):211-21. doi: 10.1096/fj.04-1970com. FASEB J. 2005. PMID: 15677344
-Zcharia, E., Zilka, R., Yaar, A., Yacoby-Zeevi, O., Zetser, A., Metzger, S., Sarid, R., Naggi, A., Casu, B., Ilan, N., Vlodavsky, I., Abramovitch, R. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models....
-Zcharia, E., Zilka, R., Yaar, A., Yacoby-Zeevi, O., Zetser, A., Metzger, S., Sarid, R., Naggi, A., Casu, B., Ilan, N., Vlodav …
O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.
Borgenström M, Wärri A, Hiilesvuo K, Käkönen R, Käkönen S, Nissinen L, Pihlavisto M, Marjamäki A, Vlodavsky I, Naggi A, Torri G, Casu B, Veromaa T, Salmivirta M, Elenius K. Borgenström M, et al. Among authors: casu b. Semin Thromb Hemost. 2007 Jul;33(5):547-56. doi: 10.1055/s-2007-982087. Semin Thromb Hemost. 2007. PMID: 17629853
Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, Naggi A, Torri G, Casu B, Sasisekharan R. Vlodavsky I, et al. Among authors: casu b. Thromb Res. 2007;120 Suppl 2:S112-20. doi: 10.1016/S0049-3848(07)70139-1. Thromb Res. 2007. PMID: 18023704 Review.
Non-anticoagulant heparins and inhibition of cancer.
Casu B, Vlodavsky I, Sanderson RD. Casu B, et al. Pathophysiol Haemost Thromb. 2008;36(3-4):195-203. doi: 10.1159/000175157. Epub 2009 Jan 27. Pathophysiol Haemost Thromb. 2008. PMID: 19176992 Free PMC article. Review.
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD. Yang Y, et al. Among authors: casu b. Blood. 2007 Sep 15;110(6):2041-8. doi: 10.1182/blood-2007-04-082495. Epub 2007 May 29. Blood. 2007. PMID: 17536013 Free PMC article.
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y. Ritchie JP, et al. Among authors: casu b. Clin Cancer Res. 2011 Mar 15;17(6):1382-93. doi: 10.1158/1078-0432.CCR-10-2476. Epub 2011 Jan 21. Clin Cancer Res. 2011. PMID: 21257720 Free PMC article.
129 results